Clinical Trial

Effect of Moderate Alcohol on Absorption and Onset of Hezkue Sildenafil Suspension

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2025 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2, open-label, randomized crossover study assessing the effect of moderate alcohol intake on the absorption and onset of action of Hezkue® sildenafil oral suspension in adult subjects. Participants will receive Hezkue® under different alcohol intake conditions in randomized sequence. Pharmacokinetic sampling and onset assessments will be performed after each administration, and safety will be monitored throughout the study.
Trial Details
NCT Number NCT07290400
Lead Sponsor Aspargo Labs, Inc
Conditions Erectile Dysfunction
Enrollment 36 participants
Start Date 2026-04-15
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-06-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-18